NorthWest Biotherapeutics Inc (NWBO)

[Johnni]

This study in Norway (link and citation below) might suggest that the many stringent selection criteria could be mostly responsible for the good-looking outcomes we saw for patients in the blinded-data NWBO paper.

Credit to a new poster (sorry — I forgot who) for bringing it to the board’s attention a couple months ago. The original poster also pointed out, crucially, that the data in this Norwegian paper extends 8 years, and the graphs extend accordingly.

https://academic.oup.com/noa/article/3/1/vdab008/6152004?login=true

Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?

Erlend Skaga, Marthe Andrea Skretteberg, Tom Børge Johannesen, Petter Brandal, Einar O Vik-Mo, Eirik Helseth, Iver A Langmoen

Neuro-Oncology Advances, Volume 3, Issue 1, January-December 2021, vdab008, https://doi.org/10.1093/noajnl/vdab008
Published: 26 February 2021